221 related articles for article (PubMed ID: 38619504)
1. Hammerhead-type FXR agonists induce an enhancer RNA
Chen J; Wang R; Xiong F; Sun H; Kemper B; Li W; Kemper J
Elife; 2024 Apr; 13():. PubMed ID: 38619504
[TBL] [Abstract][Full Text] [Related]
2. Hammerhead-type FXR agonists induce an eRNA
Chen J; Wang R; Xiong F; Sun H; Kemper B; Li W; Kemper JK
bioRxiv; 2024 Feb; ():. PubMed ID: 38045226
[TBL] [Abstract][Full Text] [Related]
3. Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents.
Hernandez ED; Zheng L; Kim Y; Fang B; Liu B; Valdez RA; Dietrich WF; Rucker PV; Chianelli D; Schmeits J; Bao D; Zoll J; Dubois C; Federe GC; Chen L; Joseph SB; Klickstein LB; Walker J; Molteni V; McNamara P; Meeusen S; Tully DC; Badman MK; Xu J; Laffitte B
Hepatol Commun; 2019 Aug; 3(8):1085-1097. PubMed ID: 31388629
[TBL] [Abstract][Full Text] [Related]
4. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E
Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH).
Tully DC; Rucker PV; Chianelli D; Williams J; Vidal A; Alper PB; Mutnick D; Bursulaya B; Schmeits J; Wu X; Bao D; Zoll J; Kim Y; Groessl T; McNamara P; Seidel HM; Molteni V; Liu B; Phimister A; Joseph SB; Laffitte B
J Med Chem; 2017 Dec; 60(24):9960-9973. PubMed ID: 29148806
[TBL] [Abstract][Full Text] [Related]
6. Improvement of NASH and liver fibrosis through modulation of the gut-liver axis by a novel intestinal FXR agonist.
Moon AN; Briand F; Breyner N; Song DK; Madsen MR; Kim H; Choi K; Lee Y; Namkung W
Biomed Pharmacother; 2024 Apr; 173():116331. PubMed ID: 38428307
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
8. Obeticholic acid-a new therapy in PBC and NASH.
Chapman RW; Lynch KD
Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists.
Zhu Y; Zhang J; Min F; Yang X; Li L; Zhang Y; Hou X; Fang H
Bioorg Med Chem Lett; 2022 Nov; 76():128993. PubMed ID: 36130662
[TBL] [Abstract][Full Text] [Related]
10. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.
Harrison SA; Bashir MR; Lee KJ; Shim-Lopez J; Lee J; Wagner B; Smith ND; Chen HC; Lawitz EJ
J Hepatol; 2021 Jul; 75(1):25-33. PubMed ID: 33581174
[TBL] [Abstract][Full Text] [Related]
11. Nonsteroidal FXR Ligands: Current Status and Clinical Applications.
Gege C; Hambruch E; Hambruch N; Kinzel O; Kremoser C
Handb Exp Pharmacol; 2019; 256():167-205. PubMed ID: 31197565
[TBL] [Abstract][Full Text] [Related]
12. Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis.
Chianelli D; Rucker PV; Roland J; Tully DC; Nelson J; Liu X; Bursulaya B; Hernandez ED; Wu J; Prashad M; Schlama T; Liu Y; Chu A; Schmeits J; Huang DJ; Hill R; Bao D; Zoll J; Kim Y; Groessl T; McNamara P; Liu B; Richmond W; Sancho-Martinez I; Phimister A; Seidel HM; Badman MK; Joseph SB; Laffitte B; Molteni V
J Med Chem; 2020 Apr; 63(8):3868-3880. PubMed ID: 31940200
[TBL] [Abstract][Full Text] [Related]
13. Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome.
Gay MD; Cao H; Shivapurkar N; Dakshanamurthy S; Kallakury B; Tucker RD; Kwagyan J; Smith JP
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163821
[TBL] [Abstract][Full Text] [Related]
14. FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid.
Wang K; Zhang Y; Wang G; Hao H; Wang H
Med Res Rev; 2024 Mar; 44(2):568-586. PubMed ID: 37899676
[TBL] [Abstract][Full Text] [Related]
15. INT-767 improves histopathological features in a diet-induced
Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
[TBL] [Abstract][Full Text] [Related]
16. Rational design of FXR agonists: a computational approach for NASH therapy.
Gandhe A; Kumari S; Elizabeth Sobhia M
Mol Divers; 2023 Dec; ():. PubMed ID: 38055145
[TBL] [Abstract][Full Text] [Related]
17. Glycine-β-muricholic acid antagonizes the intestinal farnesoid X receptor-ceramide axis and ameliorates NASH in mice.
Jiang J; Ma Y; Liu Y; Lu D; Gao X; Krausz KW; Desai D; Amin SG; Patterson AD; Gonzalez FJ; Xie C
Hepatol Commun; 2022 Dec; 6(12):3363-3378. PubMed ID: 36196594
[TBL] [Abstract][Full Text] [Related]
18. FXR agonists in NASH treatment.
Adorini L; Trauner M
J Hepatol; 2023 Nov; 79(5):1317-1331. PubMed ID: 37562746
[TBL] [Abstract][Full Text] [Related]
19. Restraint stress promotes nonalcoholic steatohepatitis by regulating the farnesoid X receptor/NLRP3 signaling pathway.
Yang F; Lv XT; Lin XL; Wang RH; Wang SM; Wang GE
Acta Biochim Biophys Sin (Shanghai); 2023 Dec; 55(12):1961-1971. PubMed ID: 37997375
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis.
Schumacher JD; Guo GL
Handb Exp Pharmacol; 2019; 256():325-357. PubMed ID: 31201553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
